vimarsana.com
Home
Live Updates
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients : vimarsana.com
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. , a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the...
Related Keywords
Canada ,
Washington ,
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Israel ,
Massachusetts ,
Ottawa ,
Ontario ,
Rehovot ,
Hamerkaz ,
American ,
Canadian ,
Brii Biosciences ,
Prehevbrio Prehevbri ,
Drug Administration ,
Company Quarterly Reports On Form ,
American Society Of Clinical Oncology ,
Oncology Center ,
World Vaccine Congress Washington ,
Nasdaq ,
Vaccines Inc ,
Clinical Oncology ,
Randomized Phase ,
Central Nervous System Tumors ,
Session Time ,
Study Design ,
Track Designation ,
Orphan Drug Designation ,
Accelerated Approval ,
Priority Review ,
Drug Evaluation ,
Biologics Evaluation ,
Clinical Trial Endpoints ,
Cancer Drugs ,
Private Securities Litigation Reform Act ,
Nasdaq Capital Market ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
vimarsana.com © 2020. All Rights Reserved.